Oral Session 3-12A Genomic Mutation in AML

[OS3-12A-5] Genome-wide CRISPR-Cas9 screen identifies novel therapeutic targets for TP53-mutated AML

Yuichiro Semba^1,2, Takuji Yamauchi^1,2, Fumihiko Nakao¹, Qiuming Yao³, Junpei Nogami¹, Matthew Canver³, Luca Pinello⁴, Daniel Bauer³, Koichi Akashi^1,2, Takahiro Maeda^1,2 (1.Dep. of Med. and Biosystem. Sci., Kyushu Univ., Fukuoka, Japan, 2.Cell. and Mol. Med., Kyushu Univ. Hosp., Fukuoka, Japan, 3.Hemato. Onco., Boston Child. Hosp., Harvard Med. Sch, Boston, USA, 4.Cent. for Cancer Res., Massachusetts Gen. Hosp., Charlestown, USA)